Tetrahydroaminoacridine‐induced ribosomal changes and inhibition of protein synthesis in rat hepatocyte suspensions

Marc W. Fariss, Sharon A. Johnsen, Lloyd P. Walton, Virgil R. Mumaw, Sidhartha D. Ray – 1 July 1994 – Tacrine (tetrahydroaminoacridine) is currently the only drug approved for the treatment of Alzheimer's disease. Unfortunately, tetrahydroaminoacridine therapy is often limited by this drug's propensity to induce reversible hepatotoxicity.

Prognostic significance of diabetes in patients with cirrhosis

Giampaolo Bianchi, Giulio Marchesini, Marco Zoli, Elisabetta Bugianesi, Andrea Fabbri, Emilio Pisi – 1 July 1994 – Alterations in carbohydrate metabolism are frequently observed in cirrhosis, and approximately 15% to 30% of patients have overt diabetes. In a retrospective and prospective study in cirrhosis, we analyzed the prognostic significance of diabetes, which was defined as the presence of hyperglycemia and overt glycosuria that in most cases required dietary restrictions or active treatment.

Reduced expression of glutathione S‐transferase Yb2 during progression of chemically induced hepatocellular carcinomas in fischer 344 rats

Margaret J. Stalker, Trudy E. Kocal, Bette Anne Quinn, Sonya G. Gordon, M. Anthony Hayes – 1 July 1994 – We followed the expression of several glutathione S‐transferase subunits in altered foci, liver neoplasms and metastases produced in male Fischer 344 rats by a modified Solt‐Farber protocol, to determine whether components of the resistant phenotype are lost during neoplastic progression.

Indications for liver transplantation in hepatobiliary malignancy

Rudolf Pichlmayr, Arved Weimann, Burckhardt Ringe – 1 July 1994 – Our personal experience with 172 patients, the results from the European Liver Transplant Registry and a review of the recent literature are summarized and discussed to define present indications for liver transplantation in hepatobiliary malignancy. The following conditions should be considered contraindications: advanced primary liver tumors with any extrahepatic spread, cholangiocellular carcinoma, hemangiosarcoma and liver metastases from nonendocrine primary tumor.

Disease gravity and urgency of need as guidelines for liver allocation

Bijan Eghtesad, Oscar Bronsther, William Irish, Adrian Casavilla, Kareem Abu‐Elmagd, David Van Thiel, Andreas Tzakis, John J. Fung, Thomas E. Starzl – 1 July 1994 – One thousand one hundred and twenty‐eight candidates for liver transplantation were stratified into five urgency‐of‐need categories by the United Network for Organ Sharing (UNOS) criteria. Most patients of low‐risk UNOS 1 status remained alive after 1 yr without transplantation; the mortality while waiting was 3% after a median of 229.5 days.

Changes in the prevalence of HBeAg‐negative mutant hepatitis B virus during the course of chronic hepatitis B

Keisuke Hamasaki, Keisuke Nakata, Yuji Nagayama, Akira Ohtsuru, Manabu Daikoku, Kenji Taniguchi, Takuya Tsutsumi, Yoshiaki Sato, Yuji Kato, Shigenobu Nagataki – 1 July 1994 – Hepatitis B virus with a G‐to‐A point mutation at nucleotide 83 in the precore region (mutant hepatitis B virus 83), which cannot produce HBeAg, is commonly found in HBe antibody‐positive hepatitis B virus carriers. We analyzed the consecutive changes in the prevalence of mutant hepatitis B virus 83 during the course of chronic hepatitis B virus infection.

Primary biliary cirrhosis: Prediction of short‐term survival based on repeated patient visits

Paul A. Murtaugh, E. Rolland Dickson, Gooitzen M. Van Dam, Michael Malinchoc, Patricia M. Grambsch, Alice L. Langworthy, Chris H. Gips – 1 July 1994 – The progression of primary biliary cirrhosis was studied in 312 patients who were seen at the Mayo Clinic between January 1974 and May 1984. Follow‐up was extended to April 30, 1988, by which time 140 of the patients had died and 29 had undergone orthotopic liver transplantation.

Subscribe to